» Articles » PMID: 16217056

The Nature and Frequency of Cognitive Deficits in Children with Neurofibromatosis Type 1

Overview
Journal Neurology
Specialty Neurology
Date 2005 Oct 12
PMID 16217056
Citations 214
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the frequency and severity of specific cognitive deficits in children with neurofibromatosis type 1 (NF1) in a large unbiased cohort.

Methods: Extensive cognitive assessments were performed in 81 children with NF1 ages 8 to 16 years and their performance was compared with that of 49 unaffected sibling controls.

Results: Eighty-one percent of the children with NF1 had moderate to severe impairment in one or more areas of cognitive functioning. Although 51% of children with NF1 performed poorly on tasks of reading, spelling, and mathematics, specific learning disabilities (as defined by IQ-achievement discrepancies) were present in only 20% of the children. Sustained attention difficulties were present in 63% of children with NF1, with 38% of children with NF1 fulfilling the diagnostic criteria for attention deficit-hyperactivity disorder. The NF1 neuropsychological profile is characterized by deficits in perceptual skills (visuospatial and visuoperceptual), executive functioning (planning and abstract concept formation), and attention (sustained and switching). Interestingly, both verbal and visual memory was unaffected in NF1 children, and their memory skills were in general stronger than their level of general intellectual function. Although both expressive and receptive language skills were significantly impaired in NF1 children, they appeared to be relatively better preserved than visuospatial abilities once IQ is taken into account.

Conclusion: There is an extremely high frequency of cognitive problems in children with neurofibromatosis type 1, making cognitive dysfunction the most common complication to affect quality of life in these children.

Citing Articles

Disrupted visual attention relates to cognitive development in infants with Neurofibromatosis Type 1.

Begum-Ali J, Mason L, Charman T, Johnson M, Green J, Garg S J Neurodev Disord. 2025; 17(1):12.

PMID: 40087579 DOI: 10.1186/s11689-025-09599-4.


A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.

Curlee M, Toledo-Tamula M, Baker M, Wikstrom D, Harrison C, Rhodes A Cancers (Basel). 2025; 17(2).

PMID: 39858077 PMC: 11763577. DOI: 10.3390/cancers17020295.


Cognition and behavior in adults with neurofibromatosis type 1.

Bos-Roubos A, van Leeuwen H, Wingbermuhle E, van den Bosch L, Ossewaarde L, Taal W Front Neurol. 2024; 15:1476472.

PMID: 39677862 PMC: 11638057. DOI: 10.3389/fneur.2024.1476472.


Brain volumes in genetic syndromes associated with mTOR dysregulation: a systematic review and meta-analysis.

Payne J, Haebich K, Mitchell R, Bozaoglu K, Giliberto E, Lockhart P Mol Psychiatry. 2024; .

PMID: 39633008 DOI: 10.1038/s41380-024-02863-4.


Neurocognitive functioning in adults with neurofibromatosis type 1- a nationwide population-based study.

Doser K, Jepsen J, Kenborg L, Miskowiak K, Albieri V, Dalton S Orphanet J Rare Dis. 2024; 19(1):441.

PMID: 39609892 PMC: 11603635. DOI: 10.1186/s13023-024-03454-w.